U.S. District Court Preserves Jury's Willful Infringement Verdict In Sight Sciences Case Vs Alcon

Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that the U.S. District Court for the District of Delaware (the Court) issued an order on post-trial motions in Sight Sciences' patent infringement case against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, Alcon) originally filed on September 16, 2021, that preserved the jury's verdict of willful infringement. Sight Sciences asserted that Alcon's sale of the Hydrus® Microstent (Hydrus) infringed three Sight Sciences patents.

The Court's order was entered on March 27, 2026. The order (i) did not disturb the jury's verdict that Alcon willfully infringed all three of Sight Sciences' asserted patents and (ii) awarded monetary damages of $34 million, plus supplemental damages and interest, for past infringement, plus an ongoing royalty of 10% of Hydrus revenue through November 10, 2028, the date of expiration of Sight Sciences' last asserted patent. A final judgment is expected to be entered by the Court in the coming months after supplemental damages and pre-judgment interest have been calculated. The Court's final judgment is subject to appeal by Alcon.